| Literature DB >> 26028525 |
C-H Chen1, L-C Lin2, Y-J Chang3, C-E Liu4, M-S Soon5.
Abstract
OBJECTIVES: A carbapenem-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex (CRA complex) infection is one of most the difficult infections to control worldwide. We evaluated the long-term effects of infection control interventions on the incidence densities of healthcare-associated infection (HAI) and CRA complex infection, and the rates of Acinetobacter calcoaceticus-Acinetobacter baumannii complex bacteremia (AB). PATIENTS AND METHODS: We performed a cross-sectional analysis at the Changhua Christian Hospital from January 2002 to December 2013. Interventions for infection control were implemented from 2002 to 2009 (period 1). From 2010 to 2013 (period 2), infection control programs were improved by in-service education and a hand hygiene campaign to prepare for international and national hospital accreditation. The effectiveness of infection and antibiotic control programs was assessed according to the incidence densities of HAI and CRA complex, rates of CRA complex and of AB, chlorhexidine consumption density, and defined daily dose of antibiotics.Entities:
Keywords: Acinetobacter baumannii-Acinetobacter calcoaceticus; Acinetobacter calcoaceticus-Acinetobacter baumannii; Antibiotic stewardship; Bon usage des antibiotiques; Carbapenem-resistance; Hand hygiene; Hygiène des mains; Infection control; Résistance aux carbapénèmes
Mesh:
Substances:
Year: 2015 PMID: 26028525 PMCID: PMC7126745 DOI: 10.1016/j.medmal.2015.04.005
Source DB: PubMed Journal: Med Mal Infect ISSN: 0399-077X Impact factor: 2.152
Demographic and clinical characteristics of patients with AB by period.
Les caractéristiques démographiques et cliniques des patients atteints de AB par période.
| Variable | P1 ( | P2 ( | |
|---|---|---|---|
| Total strains of ACB complex (blood/all samples) | 632/16,118 | 258/4797 | < 0.001*** |
| Incidence (AB/total admissions per person-years per 100,000 admissions), mean ± SD | 177.79 ± 64.5 | 137.76 ± 102.34 | 0.421 |
| Incidence density of HAI (‰) | 4.56 ± 0.48 | 1.25 ± 0.87 | < 0.001*** |
| CRA complex (including MDRACB complex, %), mean ± SD | 28.7 ± 28.0 | 66.2 ± 15.0 | 0.033* |
| Age, years, mean ± SD | 54 ± 8 | 52 ± 7.4 | 0.685 |
| Male sex, | 420 (66.5) | 150 (58.1) | 0.019* |
| Duration of ICU stay, days, mean ± SD | 6 ± 2.6 | 7 ± 3.1 | 0.567 |
| Type of infection, | < 0.001*** | ||
| Healthcare-onset infection | 520 (82.8) | 160 (62.0) | |
| Community-onset infection | 112 (17.2) | 98 (38.0) | |
| Underlying disease, | |||
| Cardiovascular disease | 95 (15.0) | 41 (15.9) | 0.746 |
| Gastrointestinal disease | 158 (25.0) | 67 (26.0) | 0.763 |
| Diabetes | 215 (34.1) | 13 (5.0) | < 0.001*** |
| Cerebrovascular disease | 114 (18.0) | 42 (16.3) | 0.531 |
| Immunocompromised state | 51 (8.1) | 23 (8.9) | 0.679 |
| Source of CRA complex infection or colonization, | 0.038* | ||
| Respiratory tract | 193 (30.5) | 80 (31.0) | |
| Catheter-associated | 98 (15.5) | 37 (14.3) | |
| Skin and soft tissue | 106 (16.8) | 30 (11.6) | |
| Urinary tract | 64 (10.1) | 18 (6.9) | |
| Intra-abdominal | 16 (2.5) | 5 (1.9) | |
| Others | 155 (24.5) | 88 (34.1) | |
| McCabe's classification of chronic underlying diseases, ultimately fatal, | 299 (47.3) | 93 (36.0) | 0.002** |
| Previous antibiotic treatment before AB, | 588 (93.0) | 239 (92.6) | 0.832 |
| Mortality, | 161 (25.5) | 63 (24.4) | 0.742 |
AB: Acinetobacter calcoaceticus-Acinetobacter baumannii complex bacteremia; CRA complex: carbapenem-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex; HAI: healthcare-associated infection; MDRACB complex: multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex. *P < 0.05; **P < 0.01; ***P < 0.001. P1: 2002–2009, P2: 2010–2013.
χ2 test or Student's t-test when appropriate.
Including central nervous system infections.
Fig. 1Twelve-year trends of the rate of CRA complex and density of healthcare-associated infection. CCH: Changhua Christian Hospital; CRA complex: carbapenem-resistant; Acinetobacter calcoaceticus-Acinetobacter baumannii complex; HAI: healthcare-associated infection; MDRACB complex: multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex; TNIS: Taiwan Nosocomial Infection Surveillance System.
Tendances sur 12 ans du taux du complexe CRA et densité de l’infection nosocomiale.
Fig. 2Twelve-year trends of the rate of CRA complex and total ACB complex isolates. ACB complex: Acinetobacter calcoaceticus-Acinetobacter baumannii complex; CCH: Changhua Christian Hospital; CRA complex: carbapenem-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex; HAI: healthcare-associated infection; MDRACB complex: multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex; TNIS: Taiwan Nosocomial Infection Surveillance System.
Tendances sur 12 ans du taux du complexe CRA et total des isolats complexe ACB.
Infection control compliance monitoring and outcomes by period.
Suivi de la conformité du contrôle de l’infection et résultats par période.
| Variable | P1 | P2 | |
|---|---|---|---|
| Total strains of ACB complex (blood/all samples) | 632/16,118 | 258/4797 | < 0.001*** |
| Incidence (AB/total admissions per person-years per 100,000 admissions), mean ± SD | 177.79 ± 64.5 | 137.76 ± 102.34 | 0.421 |
| Incidence density of HAI (‰) | 4.56 ± 0.48 | 1.25 ± 0.87 | < 0.001*** |
| CRA complex (including MDRACB complex, %), mean ± SD | 28.7 ± 28.0 | 66.2 ± 15.0 | 0.033* |
| Adherence to environmental cleaning | |||
| Observations, | 5936 | 17,224 | |
| Observations per week, | – | 3 ± 0.9 | |
| Environmental cleaning rate | – | 90 ± 12 | |
| Adherence to hand hygiene | |||
| Observations, | 5936 | 17,224 | |
| Compliance rate (%), mean ± SD | 87.2 ± 14.1 | 98.5 ± 13.2 | 0.212 |
| Correct rate (%), mean ± SD | 91.2 ± 12.1 | 99.8 ± 3.2 | 0.202 |
| Adherence to contact isolation | |||
| Observations, | 5936 | 17,224 | |
| Glove and gown use (%), mean ± SD | 79 ± 14 | 81 ± 15 | 0.824 |
| Chlorhexidine consumption | |||
| Observations, | – | 17,224 | |
| Chlorhexidine consumption density, L/patient number × 1000, mean ± SD | – | 45.5 ± 10.4 | |
| Outcome (per 1000 patient-days), % | |||
| Incidence (ACB complex bacteremia/total admission number per person-years per 100,000 admission), mean ± SD | 177.79 ± 64.5 | 137.76 ± 102.34 | 0.421 |
| Piperacillin-tazobactam consumption (DDD per 1000 patient-days) | 4,591 ± 21.6 | 4,301 ± 36.6 | < 0.001*** |
| Carbapenem consumption (DDD per 1000 patient-days) | 921 ± 41.5 | 811 ± 31.6 | 0.608 |
| CRA complex (%), mean ± SD | 28.7 ± 28.0 | 66.2 ± 15.0 | 0.033* |
| MRSA (%), mean ± SD | 51.2 ± 6.3 | 38.3 ± 5.7 | 0.006** |
| CR | 5.4 ± 1.4 | 5.3 ± 1.3 | 0.908 |
| Density of CLABSI rate (‰), mean ± SD | 18.5 ± 9.5 | 16.4 ± 6.0 | 0.699 |
| Density of CAUTI rate (‰), mean ± SD | 16.9 ± 9.3 | 10.0 ± 4.4 | 0.197 |
| Density of VAP rate (‰), mean ± SD | 2.9 ± 1.7 | 0.5 ± 0.9 | 0.026* |
AB: Acinetobacter calcoaceticus-Acinetobacter baumannii complex bacteremia; CRA complex: carbapenem-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex; CAUTI: catheter-associated urinary tract infection; CLABSI: central line-associated bloodstream infection; CR Pseudomonas aeruginosa: carbapenem-resistant Pseudomonas aeruginosa; DDD: defined daily dose; HAI: healthcare-associated infection; MDRACB complex: multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex; MRSA: methicillin-resistant Staphylococcus aureus; VAP: ventilator-associated pneumonia. *P < 0.05, **P < 0.01, ***P < 0.001. P1: 2002–2009; P2: 2010–2013.
The environmental cleaning rate was defined as the number of sites cleaned/total number of sites observed.
Hand hygiene and contact isolation adherence rates were defined as the number of observations confirming adherence to hand hygiene requirements/number of observations.
χ2 test or Student's t-test when appropriate.